Examining protein changes in peripheral blood cells just 24 hours after initiating chemotherapy for acute myeloid leukemia (AML) could predict 5-year overall survival, potentially allowing treatment ...

Panelists stress that timely and accurate diagnosis of KMT2A-rearranged acute myeloid leukemia (AML) is essential for personalized treatment planning, highlighting the need to overcome systemic delays ...

A highly sensitive bone marrow test could double survival rates for some groups of younger adults with Acute Myeloid Leukaemia (AML) by helping doctors identify if they might relapse up to three ...

A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.

MRD status before allo-HSCT is a strong prognostic factor for OS, DFS, and CIR in AML and MDS patients. MRD-negative patients showed significantly better OS and DFS compared to MRD-positive patients, ...

Anthracycline and cytarabine chemotherapy has been the backbone of induction chemotherapy for AML for more than 50 years. Advances in our understanding of leukemia biology and the development of ...

New research out of VCU Massey Comprehensive Cancer Center has uncovered a targeted cancer therapy that significantly ...

Acute myeloid leukemia (AML) is not hereditary, but a person may inherit gene mutations that make the condition more likely. Having a close family member with AML can also increase the risk. Acute ...